



Universiteit  
Leiden  
The Netherlands

## **Genetic variants contribute to differences in response and toxicity to drugs used in autoimmune diseases: Rheumatoid arthritis and systemic lupus erythematosus**

Dávila Fajardo, C.L.

### **Citation**

Dávila Fajardo, C. L. (2020, September 29). *Genetic variants contribute to differences in response and toxicity to drugs used in autoimmune diseases: Rheumatoid arthritis and systemic lupus erythematosus*. Retrieved from <https://hdl.handle.net/1887/136914>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/136914>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/136914> holds various files of this Leiden University dissertation.

**Author:** Dávila Fajardo, C.L.

**Title:** Genetic variants contribute to differences in response and toxicity to drugs used in autoimmune diseases: Rheumatoid arthritis and systemic lupus erythematosus

**Issue date:** 2020-09-29

# STELLINGEN

behorend bij het proefschrift

## **Genetic variants contribute to differences in response and toxicity to drugs used in autoimmune diseases: Rheumatoid arthritis and Systemic lupus erythematosus**

1. The drug response in autoimmune diseases (RA and SLE) is multifactorial including both non-genetic and genetic factors. *(dit proefschrift)*
2. The lack of well-designed genetic replication studies limits the implementation of the use of genetic biomarkers in RA and SLE in daily clinical practice. *(dit proefschrift)*
3. Future pharmacogenetic research in RA and SLE should focus on GWAS to explore additional genetic markers. *(dit proefschrift)*
4. Genetic variations in genes encoding drug metabolizing enzymes, drug transporters or drug targets are a cause of Interindividual differences in both drug efficacy and adverse drug events. *(dit proefschrift)*
5. Many research studies use measures, including DAS-28, American College of Rheumatology, or EULAR response criteria, which include subjective measures of disease and are known to have a placebo effect. *(Bluett J, Barton A. Rheum Dis Clin North Am. 2017;43(3):377-87)*
6. About 70% of patients with RA continue with the active disease, or relapses, even during current biological therapy. One of the reasons for this kind of evolution is the immunogenicity associated to these drugs. *(Aikawa NE, Freire de Carvalho J, Almeida Silva CA, et al. Clin Rev Allergy Immunol. 2010;38(2-3):82-9)*
7. Although PGx-based research has been conducted for more than a decade, several barriers have slowed down its widespread implementation in clinical practice. *(Klein ME, Parvez MM, Shin J. J Pharm Sci. 2017;106(9):2368-79)*
8. Pharmacogenetic testing should be gradually introduced into medical practice. ADRs can be reduced not only by adherence to prescribing guidelines, suitable monitoring and regular medication review, but also by the implementation of pharmacogenomic procedures in the clinical setting. *(Cacabelos R, Cacabelos N, Carril JC. Expert Rev Clin Pharmacol. 2019;12(5):407-42)*
9. We ourselves feel that what we are doing is just a drop in the ocean. But if the drop was not in the ocean, I think the ocean would be less because of the missing drop. *(Mother Teresa of Calcutta, in: Reaching Out In Love - Stories told by Mother Teresa, Compiled and Edited by Edward Le Joly and Jaya Chaliha, Barnes & Noble, 2002, p. 122; Refers to when you think that after so much effort the result is little for everything worked, although you have always contributed to something larger)*
10. The future belongs to those who believe in the beauty of their dreams. *(Eleanor Roosevelt, January 1988; Refers to believe in your soul for doing your best which will help you to achieve a beautiful life)*